Showing 1 - 5 results of 5 for search 'Huide Zhu', query time: 0.03s Refine Results
  1. 1
    Preoperative Prognostic Nutritional Index Predict Survival in Patients With Resectable Esophageal Squamous Cell Carcinoma

    Preoperative Prognostic Nutritional Index Predict Survival in Patients With Resectable Esophageal Squamous Cell Carcinoma by Zhiwei Zheng, Huide Zhu, Hongfu Cai

    Published 2022-04-01
    Get full text
    Article
  2. 2
    Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer

    Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer by Zhiwei Zheng, Huide Zhu, Ling Fang, Hongfu Cai

    Published 2022-09-01
    Get full text
    Article
  3. 3
    Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis

    Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis by Zhiwei Zheng, Hongfu Cai, Jingwen Lin, Huide Zhu

    Published 2024-12-01
    Get full text
    Article
  4. 4
    Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More

    Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 1... by Zhiwei Zheng, Jingrong Lin, Huide Zhu, Hongfu Cai

    Published 2022-06-01
    Get full text
    Article
  5. 5
    Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China

    Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer... by Zhiwei Zheng, Liu Yang, Siqi Xu, Huide Zhu, Hongfu Cai

    Published 2022-09-01
    Get full text
    Article

Search Tools: